Episode Details

Biotech Kodiak Sciences (KOD) plunged 80% in one day after a major drug trial setback. 

In today's episode, we focus on why this company captivated Wall Street… and what investors can learn from the selloff. [1:45]

I've been following Kodiak for a while… We once bought and sold it for a gain in Curzio Venture Opportunities. Even recently, the Baker Brothers—some of the best biotech investors—were buying heavily. [3:40]

But this week… the Phase 3 study for its most exciting drug missed expectations. [7:50]

The situation is a strong example of why investors must pay attention to expectations—both high and low… and be willing to adjust as facts change. [11:00]

When expectations are leaning either bullish or bearish, consider the contrarian trade… It's how you make the biggest gains as an investor. [26:00]

Enjoyed this episode?

Get Wall Street Unplugged delivered FREE to your inbox every Wednesday: https://www.curzioresearch.com/wall-street-unplugged/

Wall Street Unplugged podcast is available at:

--iTunes: https://itunes.apple.com/us/podcast/wall-street-unplugged-frank/

--Stitcher : https://www.stitcher.com/podcast/curzio-research/wall-street-unplugged-2

--Website : https://www.curzioresearch.com/category/podcast/wall-street-unplugged/

Twitter: https://twitter.com/frankcurzio

Facebook:. https://www.facebook.com/CurzioResearch/

Linkedin: https://www.linkedin.com/in/frank-curzio-690561a7/

Website: https://www.curzioresearch.com